356 related articles for article (PubMed ID: 18515402)
21. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability.
Blanes A; Diaz-Cano SJ
Am J Clin Pathol; 2007 Mar; 127(3):398-408. PubMed ID: 17276949
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
Schteingart DE
N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
[No Abstract] [Full Text] [Related]
23. A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization.
Soga H; Takenaka A; Ooba T; Nakano Y; Miyake H; Takeda M; Tanaka K; Hara I; Fujisawa M
Urol Int; 2009; 82(2):222-6. PubMed ID: 19322014
[TBL] [Abstract][Full Text] [Related]
24. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
[TBL] [Abstract][Full Text] [Related]
25. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
26. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
27. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
28. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
Sturgeon C; Shen WT; Clark OH; Duh QY; Kebebew E
J Am Coll Surg; 2006 Mar; 202(3):423-30. PubMed ID: 16500246
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
[TBL] [Abstract][Full Text] [Related]
30. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
31. Surgical management of adrenocortical carcinoma.
Ranvier GG; Inabnet WB
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
Tőke J; Uhlyarik A; Lohinszky J; Stark J; Huszty G; Micsik T; Borka K; Reismann P; Horányi J; Igaz P; Tóth M
Front Endocrinol (Lausanne); 2022; 13():952418. PubMed ID: 36246926
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification.
Volante M; Bollito E; Sperone P; Tavaglione V; Daffara F; Porpiglia F; Terzolo M; Berruti A; Papotti M
Histopathology; 2009 Nov; 55(5):535-43. PubMed ID: 19912359
[TBL] [Abstract][Full Text] [Related]
34. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
Tripto-Shkolnik L; Blumenfeld Z; Bronshtein M; Salmon A; Jaffe A
J Clin Endocrinol Metab; 2013 Feb; 98(2):443-7. PubMed ID: 23275528
[TBL] [Abstract][Full Text] [Related]
35. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
36. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
[No Abstract] [Full Text] [Related]
38. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
39. Outcome of adrenocortical tumors in children.
Hanna AM; Pham TH; Askegard-Giesmann JR; Grams JM; Iqbal CW; Stavlo P; Moir CR
J Pediatr Surg; 2008 May; 43(5):843-9. PubMed ID: 18485950
[TBL] [Abstract][Full Text] [Related]
40. Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence.
Freire DS; Siqueira SA; Zerbini MC; Wajchenberg BL; Corrêa-Giannella ML; Lucon AM; Pereira MA
Clin Endocrinol (Oxf); 2013 Oct; 79(4):468-75. PubMed ID: 23444945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
